肿瘤来源的IgG抑制脐带血中T细胞的增殖

doi:10.3969/j.issn.1671-167X.2017.05.014

摘要/Abstract

摘要： 目的探究肿瘤来源的IgG是否对T细胞活化具有抑制作用。方法首先从卵巢癌肿瘤组织纯化了肿瘤来源的IgG(tumor derived IgG, tIgG),并从脐带血中分离出单个核细胞(cord blood mononuclear cells,CBMC)及淋巴细胞(cord blood lymphocyte,CBL),用植物血球凝集素(phytohaemagg lutinin,PHA)刺激单个核细胞和淋巴细胞,使单个核细胞与淋巴细胞处于增殖状态,用荧光染料羟基荧光素二醋酸盐琥珀酰亚胺酯(carboxyfluorescein succinimidyl amino ester,CFSE)染色,CFSE对细胞无毒性,可以穿透细胞膜,在活细胞内与胞内蛋白结合,其荧光强度会随着细胞的分裂增殖而逐级递减,从而可以检测细胞增殖的情况。把从卵巢癌肿瘤组织中纯化得到的tIgG分为1 mg/L、10 mg/L和100 mg/L组,分别加入到单个核细胞和淋巴细胞中,静脉注射用免疫球蛋白(intravenous immunoglo-bulin,IVIG)作为阳性对照,也分为1 mg/L、10 mg/L和100 mg/L组,磷酸缓冲盐溶液(phosphate buffer saline,PBS)作为阴性对照,用细胞流式术检测CD4⁺及CD8⁺ T细胞的增殖能力,并分别在64 h和86 h两个时间点检测细胞的增殖情况。结果在CBMC体系中加入的tIgG可以明显地抑制CBMC中T细胞的增殖,发挥免疫抑制作用;同样,在CBL体系中加入的tIgG对T细胞也有抑制作用,且加入tIgG刺激的T细胞比加入IVIG刺激的T细胞的抑制增殖作用更强;在CBL体系中,tIgG的1 mg/L组和10 mg/L组对T细胞发挥的抑制增殖作用比100 mg/L组弱。结论 tIgG可以抑制T细胞的增殖,促使肿瘤发挥肿瘤免疫逃逸效应。

关键词: 免疫球蛋白G, 免疫逃逸, 肿瘤, T淋巴细胞

Abstract: Objective: To explore the function of tumor derived IgG (tIgG) and whether the tIgG can inhibit T cells activity. Methods: The tIgG was purified from ovarian cancer tissue. The cord blood monocyte cells (CBMC) and cord blood lymphocyte (CBL) were isolate from human umbilical cord blood. The CBMC and CBL were stimulated with phytohaemagg lutinin (PHA) in order to let the CBMC and CBL in the state of proliferation. Carboxyfluorescein succinimidyl amino ester (CFSE) was cultured with CBMC and CBL. CFSE had no cell toxicity, which could penetrate through the cell membrane and combine the intracellular protein. The fluorescence intensity decreased with the proliferation of cells step by step, so the proliferation of these cells could be detected in flow ctytometry. The tIgG which was purified from ovarian cancer tissue was divided into three groups, 1 mg/L group, 10 mg/L group, and 100 mg/L group, and the intravenous immunoglobulin (IVIG) was also divided into three groups too. The CBMC and CBL were treated by tIgG with 1 mg/L, 10 mg/L, and 100 mg/L in order to observe the proliferation of T cells. The cells were treated with IVIG as a positive control group, and the cells were treated with phosphate buffer saline (PBS) as a negative control. The proliferation of CD4⁺ or CD8⁺ T cells were detected in CBMC and CBL. The proliferation of the T cells in CBMC and CBL after 64 h and 86 h were detected. Results: In the system of CBMC, the tIgG could suppress the proliferation of CD4⁺ or CD8⁺ T cells. The results could also be found in the system of CBL. The CD4⁺ or CD8⁺ T cells in the group which were treated with PBS were more active than those in the group which were treated with tIgG and IVIG. The suppression in the group which were treated with tIgG, was stronger than that in the group treated with IVIG. In addition, the suppression of T cells in the group which were stimulated with tIgG as 100 mg/L was more effective than that in the group which were stimulated with tIgG as 10 mg/L. This could prove that tIgG had the function of immunomodulation. Conclusion: The tIgG can be involved in immune escape of cancer.

Key words: Immunoglobulin G, Immune escape, tumor, T-lymphocytes

中图分类号:

R392.12

刘恩阳, 刘静芳, 邵文威, 肖琳, 李国辉, 昌晓红, 邱晓彦. 肿瘤来源的IgG抑制脐带血中T细胞的增殖[J]. 北京大学学报(医学版), 2017, 49(5): 824-828.

LIU En-yang, LIU Jing-fang, SHAO Wen-wei, XIAO Lin, LI Guo-hui, CHANG Xiao-hong, QIU Xiao-yan. Tumor derived IgG suppress the proliferation of T cells in cord blood[J]. Journal of Peking University(Health Sciences), 2017, 49(5): 824-828.

参考文献

[1] 陈玉强, 王元. 丙种免疫球蛋白Fc段糖基化及其生物学活性和功能[J]. 现代生物医学进展, 2008, 8(7): 1368-1370.
[2] Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc [J]. Science, 2008, 320(5874): 373-376.
[3] 邱晓彦, 杨贵贞. 恶性肿瘤细胞内呈现的Ig样蛋白特性及Ig基因结构分析[J]. 中国免疫学杂志, 1996, 20(5): 296-297.
[4] Liao Q , Liu W, Liu Y, et al. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis [J]. Oncotarget, 2015, 6(37): 40081-40094.
[5] 邱晓彦, 杨贵贞. 恶性肿瘤细胞内存在免疫球蛋白样物质[J]. 白求恩医科大学学报, 1996, 22(6): 572-573.
[6] 邱晓彦, 侯春梅, 李秀森, 等. Ig样物质存在于多种肿瘤传代细胞[J]. 癌症, 1999, 18(1): 180-184.
[7] Qiu X, Zhu X, Zhang L, et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells [J]. Cancer Res, 2003, 63(19): 6488-6495.
[8] Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus [J]. Arthritis Rheum, 2003, 48(12): 3497-3502.
[9] Rogozin IB, Iyer LM, Liang L, et al. Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase [J]. Nat Immunol, 2007, 8(6): 647-656.
[10] Herrin BR, Alder MN, Roux KH, et al. Structure and specificity of lamprey monoclonal antibodies [J]. Proc Natl Acad Sci USA, 2008, 105(6): 2040-2045.
[11] Pancer Z, Amemiya CT, Ehrhardt GR, et al. Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey [J]. Nature, 2004, 430(6996): 174-180.
[12] Tha-In T, Metselaar HJ, Tilanus HW, et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors [J]. Transplantation, 2006, 81(12): 1725-1734.
[13] Modiano JF, Amran D, Lack G, et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin [J]. Clin Immunol Immunopathol, 1997, 83(1): 77-85.
[14] Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin [J]. Clin Immunol Immunopathol, 1994, 73(2): 180-186.
[15] De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes” [J]. Blood, 2008, 112(8): 3303-3311.
[16] Vogelaar L, Van’t Spijker A, Vogelaar T, et al. Solution focused therapy: a promising new tool in the management of fatigue in Crohn’s disease patients psychological interventions for the management of fatigue in Crohn’s disease [J]. J Crohns Colitis, 2011, 5(6): 585-591.
[17] Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation [J]. Science, 2006, 313(5787): 670-673.
[18] Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins [J]. Annu Rev Immunol, 2007(25): 21-50

相关文章 15

[1]	季加孚, 韦静涛, 季科, 步召德. 胃癌诊疗的瓶颈与破局：迈向精准化与智能化融合的新纪元[J]. 北京大学学报（医学版）, 2026, 58(2): 231-238.
[2]	高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报（医学版）, 2026, 58(2): 247-250.
[3]	王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 251-256.
[4]	罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报（医学版）, 2026, 58(2): 257-265.
[5]	杜文, 章文博, 于尧, 刘硕, 苏惠裕, 胡耒豪, 唐祖南, 吴彬彰, 陈震, 李家琦, 王昊, 彭歆. 口腔颌面部肿瘤"数智化外科"诊疗流程探索与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 278-284.
[6]	王楠楠, 袁大晋, 朱昱冰, 丁磊. 结直肠癌根治术后肝转移风险多中心列线图预测模型的构建与验证[J]. 北京大学学报（医学版）, 2026, 58(2): 290-300.
[7]	刘友东, 吕亚军, 陈杰, 臧明德, 潘宏达, 刘晓文, 陆俊, 刘凤林. 全腹腔镜保留贲门胃底胃次全切除术治疗中上部胃癌的疗效及安全性[J]. 北京大学学报（医学版）, 2026, 58(2): 301-306.
[8]	李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报（医学版）, 2026, 58(2): 399-404.
[9]	李斌, 梁寒. 机器人胃癌根治术：研究进展与实践挑战[J]. 北京大学学报（医学版）, 2026, 58(2): 416-422.
[10]	董海峰, 陈恒星, 张常华. 恶性肿瘤中蛋白质乳酸化修饰的研究进展[J]. 北京大学学报（医学版）, 2026, 58(2): 423-430.
[11]	丛馨, 苏家增, 吴立玲, 丁冲, 李巍, 俞光岩. 唾液腺非肿瘤性疾病诊治研究进展[J]. 北京大学学报（医学版）, 2026, 58(1): 1-9.
[12]	李宏杨, 黄涛, 王琳琳. 脂肪肌肉比率与卵巢良性肿瘤风险的关联性[J]. 北京大学学报（医学版）, 2026, 58(1): 169-174.
[13]	高若凡, 马天宇, 王润楷, 殷雨辰, 李芮迪, 王丹丹, 夏斌. 细胞膜囊泡递送靶向肿瘤坏死因子-α的小干扰RNA对牙髓干细胞的抗炎作用[J]. 北京大学学报（医学版）, 2026, 58(1): 22-29.
[14]	刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1113-1123.
[15]	杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报（医学版）, 2025, 57(5): 956-960.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed